Abnormal In Vitro Proliferation and Differentiation of T Cell Colony-forming Cells in Patients with Tropical Spastic Paraparesis/Human T Lymphocyte Virus Type I (HTLV-I)-associated Myeloencephalopathy and Healthy HTLV-I Carriers

By Yanto Lunardi-Iskandar, Antoine Gessain, Victor H. Lam, and Robert C. Gallo

From the Laboratory of Tumor Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892

Summary

T cell colonies were generated from the peripheral blood mononuclear cells (PBMC) of 10 patients with tropical spastic paraparesis/human T lymphocyte virus type I (HTLV-I)-associated myeloencephalopathy (TSP/HAM), two healthy HTLV-I carriers, and 17 healthy HTLV-I-seronegative subjects. PBMC were cultured in methylcellulose in the absence of added growth factors (spontaneous T cell colonies), or in the presence of phorbol myristate acetate and interleukin 2 (induced T cell colonies). PBMC T cell colony-forming cells (T-CFC) from all TSP/HAM patients and HTLV-I carriers were able to grow in the absence of added growth factors and/or mitogenic stimulation. Pooled spontaneous and induced colonies were composed of cells bearing CD3+, CD4+, CD8+, and CD1+ antigens. Colonies from normal HTLV-I-seronegative subjects displayed mature cells bearing the CD3+, CD4+, CD8+, and CD1- surface phenotype. In addition, spontaneous and induced T cell colonies expressed HTLV-I antigens in 18–38% of the cells from TSP/HAM patients and HTLV-I carriers. These results demonstrate that HTLV-I infection is associated with an abnormal proliferation and differentiation of T cell progenitors in vitro and that the T-CFC from HTLV-I-seropositive individuals are infected, suggesting that T-CFC abnormalities may play a predominant role in the pathophysiology of HTLV-I.

A number of assays have been developed in semisolid media to detect T cell colony-forming cells (T-CFC). These T-CFC have been used to determine the number of T cell progenitors and to study the differentiation capacity of peripheral blood and bone marrow T lymphocytes in normal subjects and in patients with a variety of pathological conditions (1–8). In AIDS, results with the T-CFC assays have demonstrated that the T-CFC are infected with HIV-1 and that abnormalities in proliferation and differentiation were associated with a worse prognosis, suggesting a relation with disease progression (9–14).

Growth of blood and bone marrow T cell colonies from healthy individuals requires stimulation with PHA and IL-2; these colonies are called induced, in contrast to spontaneous T cell colonies, which grow without PHA and IL-2. Spontaneous T cell colonies are not observed in normal circumstances. Induced colonies from healthy individuals are comprised of mature T cells with mainly a CD3+CD4+ surface phenotype. However, some CD3+CD8+ cells have also been detected in the colonies of these T cell progenitors (9–13). T-CFC have either an immature (CD2−CD3−) phenotype (displaying neither receptors for sheep erythrocytes, nor CD3 membrane antigens), or more frequently a presumably mature (CD2+CD3+) phenotype (9–13). CD1+ cells are not observed among the progeny of T-CFC in normal individuals (9). On the other hand, CD1+ cells are found in the colonies of T cell progenitors in vitro (9–13) and in the peripheral blood in vivo of patients with AIDS (our unpublished data).

HTLV-I is a type C human retrovirus (15, 16) etiologically linked with adult T cell leukemia/lymphoma (17), a lymphoproliferative malignancy characterized by a clonal expansion of CD4+ lymphocytes and by a monoclonal integration of the provirus(es) in the tumor cells (18, 19). The presence of specific antibodies in serum and cerebrospinal fluid of patients has also linked HTLV-I with a chronic myeloencephalopathy, called tropical spastic paraparesis/HTLV-I-
associated myelopathy (TSP/HAM) (20–24). Recently, spontaneous proliferation of PBMC from patients with TSP/HAM and from healthy HTLV-I-infected carriers has been reported (25–30). The reverse transcriptase PCR has also shown HTLV-I transcripts in the PBMC from patients with TSP/HAM (29–32). Whether and at what level spontaneous lymphocyte proliferation and HTLV-I expression are related to each other remain to be determined.

The present study demonstrates for the first time that spontaneous T cell colonies can be generated from PBMC of all TSP/HAM patients and asymptomatic HTLV-I carriers examined. Furthermore, induced and/or spontaneous colonies were composed of CD1+, CD4+, and CD8+ cells, indicating an abnormal in vitro T-CFC differentiation. In addition, 18–38% of these T cell colonies express HTLV-I viral antigens, and HTLV-I virus could easily be isolated from these cells.

These results support the conclusion that HTLV-I infection is associated with an abnormal proliferation and differentiation of T cell progenitors in vitro, as evidenced by the spontaneous T cell colony growth and the CD1+ cells in the T cell colonies. Furthermore, the T-CFC from HTLV-I carriers and TSP/HAM patients are infected, raising the possibility that the T-CFC may be an important reservoir or target for infection in vivo, in contrast to the assumption that the mature CD4+ T cells are the chief HTLV-I targets, because the leukemias due to HTLV-I almost always involve CD4+ T cells.

Materials and Methods

Patients. Heparinized peripheral blood was obtained from 10 patients with TSP/HAM, two healthy HTLV-I-seropositive carriers, and 17 HTLV-I- and HIV-1-seronegative donors. All patients fulfilled the TSP/HAM criteria (20–23, 31, 32).

Cell Separation. PBMC were separated on Ficoll-Paque (Pharmacia Fine Chemicals, Uppsala, Sweden). Interphase cells were washed twice with PBS (Advanced Biotechnologies, Inc., [ABI], Columbia, MD) and resuspended in growth medium (α-modified Eagle’s medium [α-MEM]; Gibco BRL, Gaithersburg, MD). Their viability, as tested by trypan blue dye exclusion, was always >90%. In some experiments, cells were further separated on the basis of rosette formation with 2-amino-ethylisothiouronium hydrobromide (AET; Sigma Molecular Bio, St. Louis, MO)-treated SRBC (ABI) (33) and a second Ficoll-Paque density-gradient centrifugation. Therefore, interphase cells were treated with anti-CD3 mAb (Ortho, Raritan, NJ) (50 μl/10^6 cells in a final dilution of 1:400; vol/vol) at 4°C, followed by rabbit complement (70–90 μl/10^6 cells in a final dilution of 1:8; vol/vol) (Cedarlane Laboratories, Hornby, Ontario) at 37°C. This cell fraction contained <2% of CD2+ and CD3+ cells and will be referred to as E–CD3+ cells. The phenotypic characterization of E–CD3+ cells showed 1% CD3+ cells, 1% CD2+ cells, 0% CD1+ cells, 1% CD20+ cells, 0% CD56+ cells, 5–8% CD34+ cells, and 35–40% CD71+ cells. Staining of the E–CD3+ cells with fluorescein-conjugated goat anti-mouse antibody did not reveal any positive cells, demonstrating that the CD3 determination on E–CD3+ cells was not blocked by the anti-CD3 mAb that was used to deplete T cells. E+ cells were obtained from the pellet of the second density centrifugation after hypotonic lysis of the SRBC. Their viability, as tested by trypan blue dye exclusion, was >90%. Adherent (A+) and nonadherent (A–) PBMC were obtained after cell adherence to plastic petri dishes: PBMC (10^9 cells/ml) were incubated in α-MEM supplemented with 10% (vol/vol) FCS and 2 mM glutamine for 2 h in an incubator flushed with 5% CO2 at 37°C. The nonadherent cells (A–) were collected, centrifuged, and stained for naphthyl esterase. They always revealed <5% positive cells. Adherent cells were obtained by extensive vigorous washing of the dishes.

T Cell Colony Assay. Fractionated or unfractonated PBMC (5 × 10^6 cells/ml) were seeded in 0.8% methylcellulose (Fluka Chemie AG, Buchs, Switzerland) in α-MEM supplemented with 20% FCS, 2 mM glutamine, and antibiotics in the presence (induced T cell colonies) of PHA (1%; vol/vol) and 10 U/ml of human rIL-2 (Biogen, Geneva, Switzerland), in the absence of PHA and rIL-2 (spontaneous T cell colonies), and in the presence of rIL-2 without PHA. In some experiments, 5 × 10^6 cells/ml were incubated for 1 h at 4°C or 37°C with 10–20 μg/ml of anti-Tac (Coulter Immunology, Hialeah, FL), anti-p75 (Mik β1; Endogen, Inc., Boston, MA) or both anti-Tac (CD25) and anti-p75 mAbs, which recognize the IL-2R α (CD25) and p75 β chains, respectively. The cells were washed extensively and seeded in methylcellulose in the presence or absence of growth factors. In addition, unfractonated PBMC, A–, A–E+, E+, and A–E–CD3– cells (5 × 10^6 cells/ml) were incubated for 1 h at 4°C or 37°C with 10–20 μg/ml of anti-CD3, anti-MHC class I, and class II mAb (Amac, Inc., Westbrook, ME). Cells were washed extensively and seeded in methylcellulose in the absence of growth factors. Also, unfractonated PBMC, A–, A–E+, E+, and A–E–CD3– cells (5 × 10^6 cells/ml) were cultured with different concentrations of autologous adherent cells or adherent cells from allogeneic healthy donors (2 × 10^6, 5 × 10^6, and 1 × 10^6 cell/ml) and seeded in methylcellulose without growth factor. 0.1 ml of cell-containing methylcellulose preparation was seeded per well in 96-well flat-bottomed microtest plates and incubated at 37°C in 5% CO2 in air for 5–7 d. Aggregates containing at least 50 cells were counted under an inverted microscope as colonies. Colonies of the same morphology and size were picked up individually and pooled. The cells were dissociated, washed, and immunophenotyped as described below.

Self-Renewal Capacity. The clonogenic capacity of T-CFC was studied by two culture procedures. First, PBMC (10^6 cells/ml) were incubated in growth medium supplemented with 10% FCS and 2 mM glutamine for 4 d at 37°C in 5% CO2 in air. 5 × 10^6 washed viable cells/ml were seeded in methylcellulose as described above (delayed plating). The second method was to pick individual primary spontaneous colonies, and pool and dissociate them by pipetting. After washing, 5 × 10^6 viable cells/ml were seeded for primary colony growth in the absence or in the presence of added growth factors.

Phenotypic Studies and Expression of Viral Proteins. Cell phenotype was determined by indirect immunofluorescence assays (IFA) using a panel of mAbs against the CD1, CD3, CD4, CD8 (Ortho Diagnostic Systems, Raritan, NJ), and CD25 (Coulter Immunology) molecules. Moreover, IFA was also used to detect the expression of HTLV-I proteins with a gag p19 mAb, an anti-TαT, antiserum, and polyclonal sera from TSP/HAM patients. FITC-coupled goat anti-mouse or anti-human IgG antibodies (Nordic Immunology, Tilburg, The Netherlands) were used as a second reagent. The cells were examined using an epifluorescence microscope (E. Leitz, Inc., Rockleigh, NJ).

Cell Infection. In some experiments, pooled colony (spontaneous or induced) cells were irradiated with 2,500 cGy and cocultured with cord blood mononuclear cells in RPMI 1640 supplemented

T Cell Progenitors in HTLV-I-infected Individuals
with 20% FCS and rIL-2 (10 U/ml). Every 3 d, the cultured cells were tested for the expression of gag p19 and CD1 antigens. Furthermore, two-color immunofluorescence studies were performed as reported (34) using mAb coupled to rhodamine and fluorescein.

**Electron Microscopy.** Samples were taken from T cell colonies after 3, 6, and 9 d of culture, fixed in 1.25% glutaraldehyde and 0.1 M sodium cacodylate in 0.5 M PBS, and stained with 1% aqueous uranyl acetate. After dehydration, the samples were embedded in epoxy resin. Ultrathin sections of samples were examined using an electron microscope (Hitachi).

**Statistical Analysis.** Statistical comparison of the mean values for T cell colony growth of different fractions and growth conditions was performed using Fisher's analysis of variance, with 95% confidence limits.

**Results**

**PBMC Phenotype.** The phenotypic characterization of primary, uncultured PBMC from TSP/HAM patients showed 58–78% CD3⁺ cells, 48–56% CD4⁺ cells, 16–30% CD8⁺ cells, 0% CD1⁺ cells, and 0% HTLV-I gag p19⁺ cells (Table 1). The expression of CD25 was increased (9–28%) in PBMC of both TSP/HAM patients and healthy HTLV-I carriers, indicating that T cells are already activated in vivo as known from earlier studies (see Discussion).

**T Cell Colony Formation.** Not only induced, but also spontaneous, T cell colonies were grown from the PBMC of all TSP/HAM patients and healthy HTLV-I carriers. In contrast, only induced T-CFC could be generated from the PBMC of HTLV-I-seronegative controls (Tables 2 and 3). In the presence of 10 U/ml of rIL-2, and without additional PHA or mitogen stimulation, the growth of T-CFC was significantly inhibited as compared with the spontaneous colony formation in all cases of TSP/HAM patients and healthy HTLV-I carriers (Table 3).

### Table 1. Immunological Characteristics of HTLV-I-infected Individuals

| Patients | Diagnosis | Percent positive PBMC |
|----------|-----------|-----------------------|
|          |           | p19 | CD1 | CD25 | CD3 | CD4 | CD8 |
| 1        | TSP/HAM   | 0   | 0   | 20   | 75  | 56  | 30  |
| 2        | TSP/HAM   | 0   | 0   | 17   | 78  | 58  | 28  |
| 3        | TSP/HAM   | 0   | 0   | 21   | ND  | ND  | ND  |
| 4        | TSP/HAM   | 0   | 0   | 18   | 69  | 54  | 29  |
| 5        | TSP/HAM   | 0   | 0   | 15   | 71  | 55  | 21  |
| 6        | TSP/HAM   | 0   | 0   | 19   | 62  | 52  | 18  |
| 7        | TSP/HAM   | 0   | 0   | 22   | 72  | 63  | 19  |
| 8        | TSP/HAM   | 0   | 0   | 19   | ND  | ND  | ND  |
| 9        | TSP/HAM   | 0   | 0   | 28   | 61  | 48  | 18  |
| 10       | TSP/HAM   | 0   | 0   | 26   | 74  | 49  | 23  |
| 11       | Carrier*  | 0   | 0   | 22   | 58  | 50  | 16  |
| 12       | Carrier*  | 0   | 0   | 9    | ND  | ND  | ND  |

* Healthy HTLV-I carriers.

### Table 2. Induced PBMC T Cell Colony Growth in TSP/HAM Patients, HTLV-I Carriers, and HTLV-I-seronegative Controls

| Patients | Diagnosis | PBMC T-CFC |
|----------|-----------|------------|
| 1        | TSP/HAM   | 220 ± 20   |
| 2        | TSP/HAM   | 298 ± 12   |
| 3        | TSP/HAM   | 262 ± 26   |
| 4        | TSP/HAM   | 332 ± 28   |
| 5        | TSP/HAM   | 421 ± 23   |
| 6        | TSP/HAM   | 380 ± 10   |
| 7        | TSP/HAM   | 244 ± 45   |
| 8        | TSP/HAM   | 245 ± 17   |
| 9        | TSP/HAM   | 303 ± 47   |
| 10       | TSP/HAM   | 377 ± 33   |
| 11       | Carrier*  | 310 ± 12   |
| 12       | Carrier*  | 351 ± 11   |

Results are expressed as the mean number of colonies ± SD per 5 × 10⁴ seeded cells from triplicate cultures.

* Healthy HTLV-I carriers.

To determine whether the interaction of IL-2 with its receptor (IL-2R) is involved in the spontaneous colony growth, cultures were tested after incubating PBMC with anti-Tac or anti-p75 mAbs alone or with both mAbs together. As shown in Fig. 1, spontaneous T cell colony formation could strongly be inhibited after the treatment with the anti-Tac
Table 3. Spontaneous and rIL-2-induced T Cell Colony Formation

| Patients | Spontaneous | rIL-2 |
|----------|-------------|-------|
| 1        | 35 ± 5      | 12 ± 3|
| 2        | 52 ± 7      | 14 ± 2|
| 3        | 85 ± 7      | 51 ± 5|
| 4        | 45 ± 5      | 17 ± 3|
| 5        | 57 ± 4      | 15 ± 9|
| 6        | 45 ± 7      | 23 ± 6|
| 7        | 40 ± 2      | 28 ± 3|
| 8        | 111 ± 9     | 58 ± 12|
| 9        | 29 ± 2      | 20 ± 4|
| 10       | 96 ± 6      | 78 ± 7|
| 11*      | 20 ± 2      | 15 ± 7|
| 12*      | 96 ± 14     | 46 ± 6|
| HTLV-I controls (n = 5) | 0 | 0 |

Results are expressed as mean ± SD of colonies per 5 x 10^4 seeded cells from triplicate cultures.
* Healthy HTLV-I carriers.

and anti-p75 mAbs. These IL-2R antibodies inhibited the spontaneous T cell colony growth formation of PBMC from the three TSP/HAM patients and the one healthy HTLV-I carrier tested.

To determine more precisely the nature of the clonogenic T-CFC, such as mature (E⁺ CD3⁺) and immature (E⁻ CD3⁻) T-CFC, the following PBMC fractions were also tested for T cell colony growth: E⁺, adherent negative (A⁻), A⁻ E⁺, E⁻ CD3⁻, A⁻ E⁻ CD3⁻, and A⁺. As shown in Table 4, PBMC with (E⁺ and A⁻ E⁺) or without T cell markers (E⁻ CD3⁻ and A⁻ E⁻ CD3⁻) were able to generate spontaneous colonies, demonstrating that spontaneous T cell colonies originated from both mature and immature T-CFC. A⁻, E⁺, or A⁻ E⁺ cell fractions generated a significantly lower number of spontaneous T cell colonies than unfractionated PBMC (Scheffe F test, p = 0.0018), suggesting that adherent cells are needed for spontaneous T cell colony formation. The differences were less marked for the immature T-CFC (A⁻ E⁻ CD3⁻ or E⁻ CD3⁻). Adherent cells (A⁻) from TSP/HAM patients did not generate spontaneous T cell colonies. Moreover, spontaneous T cell colony formation from A⁻ cells could be restored by the addition of autologous but not allogeneic A⁺ cells (Fig. 2). This suggests that A⁺ cells are required to generate spontaneous T cell colonies from mature T-CFC. As shown in Fig. 3, spontaneous T cell colony formation from unfractionated PBMC, A⁻ E⁺, and A⁻ E⁻ CD3⁻ cells could not be inhibited or stimulated after treatment with anti-CD3, or anti-MHC class I or II mAbs. In addition, the number of spontaneous T cell colonies from all fractions examined was not affected by the addition of allogeneic adherent cells.

Phenotypic Characterization of T Cell Colonies. Induced as well as spontaneous T cell colonies generated from PBMC from TSP/HAM patients and HTLV-I carriers were composed of activated T cells, with Tac (CD25) antigens on their surface membrane (Table 5). In addition, 18-38% of the cells expressed HTLV-I antigens, as demonstrated by IFA using lower number of spontaneous T cell colonies than unfractionated PBMC (Scheffe F test, p = 0.0018), suggesting that adherent cells are needed for spontaneous T cell colony formation. The differences were less marked for the immature T-CFC (A⁻ E⁻ CD3⁻ or E⁻ CD3⁻). Adherent cells (A⁻) from TSP/HAM patients did not generate spontaneous T cell colonies. Moreover, spontaneous T cell colony formation from A⁻ cells could be restored by the addition of autologous but not allogeneic A⁺ cells (Fig. 2). This suggests that A⁺ cells are required to generate spontaneous T cell colonies from mature T-CFC. As shown in Fig. 3, spontaneous T cell colony formation from unfractionated PBMC, A⁻ E⁺, and A⁻ E⁻ CD3⁻ cells could not be inhibited or stimulated after treatment with anti-CD3, or anti-MHC class I or II mAbs. In addition, the number of spontaneous T cell colonies from all fractions examined was not affected by the addition of allogeneic adherent cells.

Table 4. Spontaneous Colony Formation from Different Cell Fractions of TSP/HAM Patients' and Healthy Carrier's PBMC

| Patient | Unfractionated PBMC | A⁻ | E⁺ | E⁻ CD3⁻ | A⁻ E⁺ | A⁻ E⁻ CD3⁻ | A⁺ |
|---------|---------------------|-----|-----|---------|-------|-------------|----|
| 2       | 110 ± 12            | 7 ± 4| 6 ± 2| 55 ± 6  | 3 ± 1  | 70 ± 11     | 0  |
| 10      | 96 ± 6              | 6 ± 1| 20 ± 2| 74 ± 8  | 6 ± 2  | 42 ± 7      | 0  |
| 13      | 76 ± 5              | 11 ± 4| 43 ± 5| 112 ± 16| 45 ± 4 | 83 ± 5      | 0  |
| 5       | 82 ± 3              | 11 ± 3| 10 ± 1| 72 ± 6  | 11 ± 4 | 74 ± 7      | 0  |
| 11*     | 124 ± 8             | 17 ± 5| 12 ± 2| 93 ± 8  | 24 ± 5 | 98 ± 5      | 0  |

Results are expressed as mean number of colonies ± SD per 5 x 10^4 seeded cells from triplicate cultures.
* HTLV-I carrier.
Figure 2. Effect of A⁺ (autologous or allogeneic adherent cells) on spontaneous T cell colony formation from TSP/HAM patients and HTLV-I carrier. Results are expressed as in Fig. 1.

Table 5. Phenotypic Characterization of Induced and Spontaneous T Cell Colonies from PBMC and E⁻CD3⁻ Cells of TSP/HAM Patients, HTLV-I Carrier, and HTLV-I-seronegative Controls

| Patient | Tac | CD1 | CD3 | CD4 | CD8 | p19 | Tac | CD1 | CD3 | CD4 | CD8 | p19 | Tac | CD1 | CD3 | CD4 | CD8 | p19 | CD25(Tac) | CD1 | CD3 | CD4 | CD8 | p19 |
|---------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| 2       |     |     |     |     |     |     | 30  | 31  | 78  | 67  | 60  | 21  | 28  |     |     |     |     |     |     |     |     |     |     |     |
| 3       | 31  | 24  | 74  | 62  | 29  | 31  | 26  | 25  | 71  | 65  | 24  | 25  |     |     |     |     |     |     |     |     |     |     |     |
| 4       | 22  | 32  | 78  | 65  | 21  | 21  | 29  | 27  | 78  | 60  | 21  | 18  |     |     |     |     |     |     |     |     |     |     |     |
| 5       | 30  | 28  | 79  | 61  | 31  | 30  | 27  | 25  | 74  | 58  | 30  | 24  |     |     |     |     |     |     |     |     |     |     |     |
| 6       | 31  | 32  | 82  | 73  | 28  | 24  | 24  | 30  | 80  | 72  | 24  | 15  |     |     |     |     |     |     |     |     |     |     |     |
| 11⁺     | 19  | 34  | 78  | 59  | 21  | 21  | 22  | 35  | 78  | 65  | 21  | 13  |     |     |     |     |     |     |     |     |     |     |     |
| 11”     |     |     |     |     |     |     | 36  |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |

Individually picked colonies were pooled, washed, and dissociated, and colony cells were stained by indirect immunofluorescence with the corresponding mAb.

* HTLV-I carrier.

† HTLV-I-seronegative controls.
Figure 4. Electron microscopy of HTLV-I viral particles from: (A) spontaneous T cell colony from TSP/HAM patient's PBMC, and (B) spontaneous T cell colony from infected cord blood mononuclear cells after coculture for 3 d in liquid culture with T cell colonies from TSP/HAM PBMC. The cord blood cells were plated in the T-CFC assay, and spontaneous colonies were examined by electron microscopy. (C) Same as in B, but after 9 d of liquid culture.
Table 6. Clonogenic Capacity of T-CFC from TSP/HAM Patients, HTLV-I Carrier, and HTLV-I-seronegative Controls

| Patient | Immediate plating | Delayed plating |
|---------|-------------------|-----------------|
|         | Spontaneous       | Induced         | Spontaneous | Induced         |
| 4       | 45 ± 5            | 332 ± 28        | 51 ± 12     | 280 ± 18        |
| 5       | 57 ± 4            | 421 ± 23        | 49 ± 6      | 300 ± 24        |
| 2       | 52 ± 7            | 298 ± 12        | 67 ± 9      | 285 ± 20        |
| 6       | 45 ± 7            | 380 ± 10        | 38 ± 4      | 290 ± 16        |
| 11*     | 20 ± 2            | 310 ± 12        | 28 ± 8      | 296 ± 12        |
| (n = 3) |                   |                 | 0           | 140 ± 29        |

Cells (5 x 10⁵/ml) were seeded in methylcellulose after 72 h of liquid culture in RPMI 1640 with 10% FCS in the absence of added growth factors or mitogens. Results are expressed as mean number of colonies per 5 x 10⁴ seeded cells from triplicate culture.

*HTLV-I carrier.
†HTLV-I-seronegative controls.

Discussion

The initial intent of these investigations was to study quantitatively and qualitatively the peripheral blood T-CFC of TSP/HAM patients and healthy HTLV-I-infected individuals. It has previously been demonstrated (25-29) that an unusual spontaneous T lymphocyte proliferation exists in TSP/HAM patients and healthy HTLV-I carriers. This study allowed us to determine that the spontaneous T lymphocyte proliferation also occurs at the level of the T-CFC, which is an indicator of the T cell progenitor population. Our results, as well as previous studies, demonstrate that there is an increased CD25 expression on PBL of TSP/HAM patients and healthy HTLV-I carriers (25-31). This suggests that there is abnormal activation of T cells in vivo since CD25 is an epitope of the IL-2R chain. The mechanism through which spontaneous T lymphocyte proliferation and spontaneous T cell colony formation arise appears to occur at least partly through the interaction of IL-2 with its receptor. Spontaneous proliferation of TSP/HAM T lymphocytes in liquid culture can be inhibited by antibodies directed against the IL-2R (29).

Moreover, an expression of IL-2 has been demonstrated in these cultures, strongly suggesting an autocrine IL-2/IL-2R loop in TSP/HAM. We have extended these observations to the level of the T-CFC, which in TSP/HAM and healthy carriers not only show an abnormal spontaneous proliferation, but also an expression of the IL-2R on the T cell colonies they generate. Furthermore, the spontaneous T cell colony formation of PBMC from HTLV-I-infected individuals is strongly inhibited by antibodies directed against the IL-2R α and β chains. In contrast to the healthy HTLV-I-seronegative individuals, the results reported here indicate that T-CFC from all TSP/HAM patients and healthy HTLV-I carriers examined showed abnormal proliferative properties. These spontaneously proliferating T-CFC of TSP/HAM patients and HTLV-I carriers possessed great self-renewal capacity in the absence of added growth factors. Conversely, spontaneously proliferating T-CFC from HIV-1-infected individuals have lost their self renewal capacity, which is a property of primitive progenitor cells (9-13).

To determine more precisely the clonogenic capacity of presumably mature and immature T-CFC, various PBMC fractions, E⁺ (CD2⁺) ("mature" T lymphocytes) or E⁻ (CD2⁻) CD3⁺ (immature T lymphocytes), were tested for spontaneous T cell colony growth with or without adherent cells. Spontaneous T cell colonies originated from both mature (E⁺) and immature (E⁻ CD3⁻) T-CFC. Preincubation with anti-CD3 mAb did not stimulate (or inhibit) the growth of spontaneous T cell colonies, originating from unfractionated PBMC, E⁺, or E⁻CD3⁻ fractions. Since the anti-CD3 mAb did not stimulate the growth of spontaneous colonies of specimens that were not depleted of mature T lymphocytes, it is highly unlikely that the generation of T cell colonies from E⁻CD3⁻ is due to a mitogenic effect of the anti-CD3 antibody on any residual T cells. A-, A- E⁺, and E⁺ cells from peripheral blood of HTLV-I-infected individuals generated significantly lower number of spontaneous T cell colonies than unfractionated cells, strongly suggesting that the generation of spontaneous T cell colonies from mature T-CFC requires cellular cooperation between T-CFC and adherent cells. We were not able to block the generation of spontaneous T cell colonies by mAbs directed against MHC class I or class II molecules, suggesting that the interaction with adherent cells does not occur via a MHC class I- or II-restricted mechanism. In-
Interestingly, only autologous but not allogeneic adherent cells were able to restore spontaneous T colony formation in adherent cell-depleted PBMC. It is unclear why autologous adherent cells from HTLV-I-infected individuals behave differently from allogeneic adherent cells from healthy seronegative donors. It may be due to a higher level of activation of adherent cells in HTLV-I-infected individuals.

In contrast, the removal of adherent cells did not result in a decrease of the number of spontaneous T cell colonies from fractionated immature T cells (A-E-CD3- vs E-CD3-), suggesting that cellular cooperation between adherent cells and T-CFC is not necessary for the generation of spontaneous T cell colonies from immature T-CFC. The reason why immature T-CFC, as opposed to mature T-CFC, do not require cooperation with adherent cells for spontaneous T cell colony formation is not clear, but could be due to a higher level of activation of immature T-CFC.

Surprisingly, when the T-CFC were cultured in the presence of IL-2 without PHA or mitogens, the growth of spontaneous T cell colonies was significantly inhibited (p<0.0001), as compared with cultures without PHA or IL-2. We do not yet understand this phenomenon, but one possibility is that IL-2 stimulates suppressor T cells to produce factors inhibiting the proliferation of T-CFC.

In TSP/HAM patients and healthy HTLV-I carriers, pooled spontaneous and induced T cell colonies were composed of a high proportion of cells bearing the CD1+ surface phenotype. Conversely, T cell colonies generated from healthy seronegative individuals displayed <4% CD1+ cells (9-13). The CD1+ antigen is characteristic of immature T lymphocytes (34-36), and its presence on cells of the T cell colonies may indicate a block of the in vitro differentiation of HTLV-I-infected cells. There appears to be a relationship between CD1+ expression and HTLV-I infection since CD1+ was expressed on the membrane of ~30% of HTLV-I gag p19+ antigen-positive cells in both induced and spontaneous T cell colonies of TSP/HAM patient and HTLV-I carrier PBMC. This suggests that CD1+ immature T cells may be a target of HTLV-I.

Direct evidence of the infection of T-CFC was shown by the capacity of pooled irradiated T cell colonies of TSP/HAM patients to transmit HTLV-I to normal cord blood or bone marrow mononuclear cells. Moreover, when these cocultured cells were replated in methylcellulose, we observed spontaneous growth of T-CFC from the infected bone marrow and cord blood cells. Recently, it was demonstrated that an early event in HTLV-I infection promotes the spontaneous growth of T-CFC (37). It is possible that HTLV-I triggers a molecular system(s) necessary for the proliferation of T-CFC.

Three important conclusions can be drawn from this study. First, in contrast to PBMC from normal individuals, PBMC from HTLV-I-infected individuals contain T cell progenitors with abnormal proliferative properties, since they can grow in the absence of added growth factors (spontaneous T cell colony formation). Second, T-CFC from TSP/HAM and HTLV-I carrier PBMC show abnormal differentiation in vitro, as evidenced by the CD1+ of part of the cells in the T cell colonies. Third, T-CFC from HTLV-I-infected individuals seem to be infected in vivo, raising the possibility that the T-CFC may be the main target and an important reservoir for HTLV-I infection. One of the most remarkable findings of this study is the rapid appearance of HTLV-I-expressing cells after cultivation in vitro. This is in contrast to previous reported studies, where liquid suspension cultures of HTLV-I-infected cells only led to a gradual and slow selection of cells expressing viral antigens (38). Our interpretation is that culture in semisolid medium allows for the rapid selection of the target cell of infection by HTLV-I (HTLV-I-infected T-CFC) from the rest of the cell population.

We thank Drs Zvi N. Berneman and Dharam Ablash for their constructive comments on the manuscript, and Ms Anna Mazzuca for expert editorial assistance. We also thank Drs Olivier Gout and Laurent Maurs for some of the patients' samples used in this study.

Y. Lunardi-Iskandar was supported by the Association de la Recherche Contre le Cancer, French Association of Research against Cancer, Villejuif, France.

Address correspondence to Robert C. Gallo, Laboratory of Tumor Cell Biology, National Cancer Institute, Building 37, Room 6A09, National Institutes of Health, Bethesda, MD 20892. Antoine Gessain's present address is the Institut Pasteur, 28, rue du Dr Roux, 75724 Paris Cedex 15, France.

Received for publication 12 March 1992 and in revised form 8 October 1992.

References

1. Fibach, E., E. Gerasi, and L. Sachs. 1976. Induction of colony formation in vitro by human lymphocytes Nature (Lond) 259:127.
2. Treibel, F., W.A. Robinson, A.R. Hayward, and P. Goube. De Laforet. 1981. Existence of a pool of lymphocyte colony forming cells (T-CFC) in human bone marrow and their place in the differentiation of T lymphocyte lineage Blood. 58:911.
3. Rozenszajn, L.A., D. Shohaw, and I. Kaledeman. 1975. Clonal proliferation of PHA-stimulated human lymphocytes in soft agar culture Immunology 29:1041.
4. Claeson, M.H., M.B. Rodger, G.R. Johnson, S. Wittinghan, and D. Metalf. 1977. Colony formation in agar medium. J. Clin. Exp. Immunol. 28:526.

5. Ragni, M.R., A. Winkelstein, T.L. Evans, J.H. Lewis, F.A. Bontempo, J.A. Spero, and B.S. Rabin. 1984. T lymphocyte colony assay in hemophiliacs. Blood. 64:105.

6. Sutherland, D.C., G. Dalton, and J.D. Wilson. 1976. T lymphocyte colonies in malignant diseases. Lancet. ii:1113.

7. Bernstein, M.L., A. Winkelstein, and S.A. Dobson. 1980. Depressed T cell colony growth in systemic lupus erythematosus. Arthritis Rheum. 23:385.

8. Georgoulas, V., H. Auclair, and C. Jasmin. 1984. Heterogeneity of peripheral blood T-cell colony forming cells in patients with T-cell malignancies. Leukocyte Res. 8:1025.

9. Lunardi-Iskandar, Y., V. Georgoulas, M. Allouche, W. Rozenbaum, D. Klitzmann, M. Cavaille-Coll, P. Meyer, J.C. Gluckman, and C. Jasmin. 1985. Abnormal in vitro proliferation and differentiation of T-colony forming cells in AIDS patients and clinically normal male homosexuals. Clin. Exp. Immunol. 60:285.

10. Lunardi-Iskandar, Y., V. Georgoulas, D. Vittecoq, M.T. Nugeyre, A. Ammar, C. Clemenceau, F. Barre-Sinoussi, J.C. Herrmann, L. Schwarzenberg, and C. Jasmin. 1987. Peripheral blood adherent cells from AIDS patients inhibit normal T-colony growth through decreased expression of interleukin-2 receptors and production of interleukin-2. Leukocyte Res. 11:753.

11. Lunardi-Iskandar, Y., V. Georgoulas, W. Rozenbaum, D. Vittecoq, P. Meyer, M. Gentilini, and C. Jasmin. 1986. AIDS and LAS patients display similar abnormal in vitro proliferation and differentiation of T-colony forming cells (T-CFC). Cancer Detect. Prev. 1:525.

12. Lunardi-Iskandar, Y., V. Georgoulas, W. Rozenbaum, D. Klitzmann, M. Cavaille-Coll, P. Meyer, J.C. Gluckman, and C. Jasmin. 1986. Abnormal in vitro proliferation and differentiation of T-colony forming cells in patients with lymphadenopathy syndrome (LAS). Blood. 67:1063.

13. Lunardi-Iskandar, Y., M.T. Nugeyre, V. Georgoulas, F. Barre-Sinoussi, C. Jasmin, and J.C. Herrmann. 1989. Replication of the human immunodeficiency virus -1 and impaired differentiation of T cells after in vitro infection of bone marrow immature T cells. J. Clin. Invest. 83:610.

14. Winkelstein, A., R.S. Klein, T.L. Evans, B.W. Dixon, W.L. Holder, and D.L. Weaver. 1985. Defective in vitro T cell colony formation in acquired immunodeficiency syndrome. J. Immunol. 134:151.

15. Poiesz, B.J., F.W. Ruscetti, A.F. Gazdar, P.A. Bunn, J.D. Minna, and R.C. Gallo. 1980. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cells lymphoma. Proc. Natl. Acad. Sci. USA. 77:415.

16. Poiesz, B.J., F.W. Ruscetti, M.S. Reitz, V.S. Kalyanaraman, and R.C. Gallo. 1981. Isolation of new type (retrovirus HTLV) in primary uncultured cells of a patient with Sezary T-cell leukemia. Nature (Lond.). 294:268.

17. Uchiyama, T., J. Yodoi, K. Sagawa, K. Takatsuki, and H. Uchino. 1977. Adults T cell leukemia: clinical and hematologic features of 16 cases. Blood. 50:481.

18. Wong-Staal, F., B. Hahn, V. Manzari, S. Colombini, G. Franchini, E.P. Gelman, and R.C. Gallo. 1983. A survey of human leukemias for sequences of a human retrovirus. Nature (Lond.). 302:625.

19. Yoshida, M., M. Seiki, K. Yamaguchi, and K. Takatsuki. 1984. Monoclonal integration of human T-cell leukemia suggests causative role of human T-cell leukemia virus in the disease. Proc. Natl. Acad. Sci. USA. 81:2534.

20. Gessain, A., F. Barim, J.C. Vernant, O. Gout, L. Mauz, A. Calender, and G. de Thé. 1985. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet. ii:407.

21. Osame, M., K. Usuku, S. Izumo, N. Izichi, H. Amitani, A. Igata, M. Matsumoto, and M. Tara. 1986. HTLV-I associated myelopathy, a new clinical entity. Lancet. iii:1031.

22. Rodgers-Johnson, P., D.C. Gajdusek, Ost. C. Morgan, V. Zaninovic, P.S. Sarin, and D.S. Graham. 1985. HTLV-I and HTLV-II antibodies and tropical spastic paraparesis. Lancet. ii:1247.

23. Osame, M., M. Matsumoto, K. Usuku, S. Izumo, N. Izichi, H. Amitani, M. Tara, and A. Igara. 1987. Chronic progressive myelopathy associated with elevated antibodies to HTLV-I and adult T-cell leukemia-like cells. Ann. Neurol. 21:117.

24. Gout, O., M. Baulac, A. Gessain, F. Semah, F. Saal, J. Peries, C. Cabrol, C. Foulcaut-Fretz, D. Laplane, F. Sigaux, and G. de Thé. 1990. Rapid development of myelopathy after HTLV-I infection acquired by transfusion during cardiac transplantation. N. Engl. J. Med. 322:383.

25. Jacobson, S., V. Zaninovic, C. Mora, P. Rodgers-Johnson, W.A. Sheremata, C.J. Gibbs, D.C. Gajdusek, and D.E. McFarlin. 1988. Immunologic finding in neurological diseases associated with antibodies to HTLV-I: activated lymphocytes in tropical spastic paraparesis. Ann. Neurol. 23(Suppl.)196.

26. Kramer, A., S. Jacobson, J.C. Reuben, E.L. Murphy, S.Z. Wiktor, B. Cranston, J.F. Figueroa, B. Hanchard, D. McFarlin, and W.A. Blattner. 1990. Spontaneous lymphocyte proliferation is elevated in asymptomatic HTLV-I-positive Jamaicans. In Human Retrovirology: HTLV. W.A. Blattner, editor. Raven Press, Ltd., New York. pg. 79.

27. Yasuda, K., Y. Sei, M.M. Yokoyama, K. Tanaka, and A. Hara. 1986. Healthy HTLV-I carriers in Japan: the hematological and immunological characteristics. Br. J. Hematol. 64:195.

28. Itoyama, Y., S. Minato, J. Kira, I. Goto, K. Okochi, and N. Yamamoto. 1988. Spontaneous proliferation of peripheral blood lymphocytes increased in patients with HTLV-I-associated myelopathy. Neurology. 38:1302.

29. Tendler, C., S.J. Greenberg, W.A. Blattner, A. Manns, E. Murphy, T. Fleisher, B. Hanchard, O. Morgan, J.D. Burton, D.L. Nelson, and T.A. Waldmann. 1990. Transactivation interleukin-2 and its receptor induces immune activation in human T-cell lymphotrophic virus type I associated myelopathy: pathogenic implications and a rationale for immunotherapy. Proc. Natl. Acad. Sci. USA. 87:5218.

30. Itoyama, Y., S. Minato, and J. Kira. 1988. Altered subsets of peripheral blood lymphocytes in patients with HTLV-I-associated myelopathy (HAM). Neurology. 38:816.

31. Gessain, A., A. Louie, O. Gout, R.C. Gallo, and G. Franchini. 1991. Expression of HTLV-I in fresh PBMC of HAM/TSP. J. Virol. 65:1628.

32. Gessain, A., F. Saal, O. Gout, M.T. Daniel, G. Flandrin, G. de Thé, G. Peries, and F. Sigaux. 1990. HTLV-I proviral DNA load with polyclonal integration in peripheral blood mononuclear cells of French West Indian, Guianese, and African patients with tropical spastic paraparesis. Blood. 75:428.

33. Hoosen, M., and H.E. Johnson. 1979. A methodological study of E-rosette formation using AE1-treated sheep red blood cells. J. Immunol. Methods. 27:61.

34. Lanier, L.L., A.M. Le, A.H. Ding, and E.L. Evans. 1987. Analysis of the workshop T-cell monoclonal antibodies by indirect two colour immunofluorescence and multiparameter flow
cytometry. In Leucocyte Typing III: White Cell Differentiation Antigens. A.J. Michael, editor. Springer Publishing Company, New York. pg. 62.

35. BrownseU, L., M. Aniot, B. Raynal, V. Gay-Bellile, B. Caillou, and A. Bernard. 1986. Epitope groups of CD1 molecules. In Leukocyte Typing II. E.L. Reinherz, B.F. Haynes, L.M. Nadler, and I.D. Bernstein, editors. Springer Publishing Company, New York. pg. 286.

36. Martin, L.H., F. Calabi, F.A. Lefebre, C.A.G. Bilsland, and C. Milstein. 1987. Structure and expression of the human thymocyte antigens CD1a, CD1b, and CD1c. Proc. Natl. Acad. Sci. USA. 84:9189.

37. DucDodon, M., and L. Gazzolo. 1987. Loss of interleukin-2 requirement for the generation of T colonies defines an early event of human T-lymphotropic virus type I infection. Blood. 69:12.

38. Hinuma, Y., K. Nagata, M. Hanaoka, M. Nakai, T. Matsumoto, K. Kinoshita, S. Shirakawa, and I. Miyoshi. 1981. Adult T-leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc. Natl. Acad. Sci. USA. 78:6476.

750 T Cell Progenitors in HTLV-I-infected Individuals